CN Health Technology Group Holding Company Limited (CN HEALTH TECH) unveiled a non-underwritten rights issue that will raise up to HK$51.46 million before expenses.
Key terms • Basis: Two rights shares for every one existing share held on 22 May 2026. • Rights shares: Up to 205.85 million new shares. • Subscription price: HK$0.25 per rights share— a 19.38% discount to the 18 May 2026 closing price of HK$0.31 and a 7.98% discount to the theoretical ex-rights price of HK$0.272. • Listing: Applications have been submitted to list the nil-paid and fully-paid rights shares on the Stock Exchange; trading in nil-paid rights is expected from 28 May to 4 June 2026. • Funding structure: The issue will proceed without underwriting. Any rights shares not taken up (Unsubscribed Rights Shares) plus those relating to overseas shareholders (ES Unsold Rights Shares) will be placed on a best-effort basis by Tiger Faith Securities. Unplaced shares will be cancelled, reducing the final issue size.
Financial impact • Gross proceeds: Approximately HK$51.46 million; estimated net proceeds of about HK$50.00 million after HK$1.50 million expenses. • Enlarged capital: Issued shares will rise from 102.92 million to a maximum 308.77 million, cutting net tangible assets per share from RMB0.553 to RMB0.325. • Promissory notes: The group has HK$120.00 million (RMB113.80 million) of promissory notes maturing in July 2028, secured by its forest lands.
Use of proceeds • HK$22.00 million (44%) – expand ginseng plantation, including land acquisition and marketing. • HK$18.00 million (36%) – invest in a new medical aesthetics segment in mainland China. • HK$10.00 million (20%) – general working capital, including salaries and office expenses.
Timetable highlights • Ex-rights trading: 14 May 2026 • Nil-paid trading: 28 May–4 June 2026 • Latest acceptance/payment: 9 June 2026 • Placing period: 17 June–6 July 2026 • Listing of fully-paid rights: 18 June 2026
Strategic rationale Management cites growing capital needs for its forestry, ginseng, and health-product operations, planned expansion into medical aesthetics, and scheduled interest payments on existing promissory notes. Alternatives such as bank borrowings or additional placings were deemed less attractive due to potential gearing pressure and immediate dilution for shareholders. The rights issue enables existing investors to maintain proportional ownership while providing the company with funds for targeted growth initiatives.
Shareholder impact Full subscription would enlarge the share base by 200%. Qualifying shareholders who do not participate will face dilution; those who do not wish to subscribe may sell their nil-paid rights in the market. Completion remains subject to shareholder approval (already obtained on 12 May 2026) and listing approval from the Stock Exchange.
Comments